Insilico Medicine Cayman TopCo — Form D
Insilico Medicine Cayman TopCo of HONG KONG, K3, a company, filed a Form D exempt-offering notice with the SEC on 2019-09-24. The offering totals $36.8M, of which $36.8M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2019-09-24
- Form: D
- Accession: 0001789097-19-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $36.8M
- Amount sold: $36.8M
- Investors: 21
- Date of first sale: 2019-09-05
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-349539
Issuer
- Name: Insilico Medicine Cayman TopCo
- CIK: 0001789097
- Entity type: Other
- Jurisdiction: CAYMAN ISLANDS
- Incorporated: 2019
- Address: RM 8 UNIT 111-113 ICT CO-WORKING CENTRE, HONG KONG, K3, 00000
- Phone: 16265937957
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| Lennart Lee | Director | Trade Zone Shanghai, F4 |
| Nisa Leung | Director | Bellevue, WA |
| James Mellon | Director | New York, NY |
| [none] WNL Limited | Director | Grand Cayman, E9 |
| Alex Zavoronkov | Director | Rockville, MD |
More